Menü
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program


Novocure (NASDAQ: NVCR) today announced the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for

ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...


 



ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60

Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases


POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on December 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022


United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of

Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.



On December 1

LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annual Meeting: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annual Meeting


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) Annual Meeting taking place December

Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has extended its

ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share


Regulatory News:



ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for

Orlando Health Forms Joint Venture With Acadia Healthcare to Expand Behavioral Health Services in the Region: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Orlando Health Forms Joint Venture With Acadia Healthcare to Expand Behavioral Health Services in the Region


Orlando Health and Acadia Healthcare Company announced today that they have formed a joint venture designed to enhance and expand behavioral health services in the region.


This press release

Acadia Healthcare Forms Joint Venture With Orlando Health: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture With Orlando Health


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Orlando Health, one of Central Florida’s premier health systems. With Acadia’s partnership

LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the 4th International Brain Stimulation Conference, taking place

PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth
PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth


Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)

GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

DGAP-News: Fresenius Medical Care AG & Co. KGaA passt Besetzung des Vorstands an neues Betriebsmodell an: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
DGAP-News: Fresenius Medical Care AG & Co. KGaA passt Besetzung des Vorstands an neues Betriebsmodell an
DGAP-News: Fresenius Medical Care AG & Co. KGaA passt Besetzung des Vorstands an neues Betriebsmodell an
DGAP-News: Fresenius Medical Care AG & Co. KGaA announces changes to Management Board, reflecting the transformation to the company's new operating model: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23608/Fresenius_Medical_Care_20xx_logo.svg.png
DGAP-News: Fresenius Medical Care AG & Co. KGaA announces changes to Management Board, reflecting the transformation to the company's new operating model
DGAP-News: Fresenius Medical Care AG & Co. KGaA announces changes to Management Board, reflecting the transformation to the company's new operating model
Quidel Statement on the Omicron Variant
Quidel Statement on the Omicron Variant


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from

Loudoun Medical Group Joins Humana Medicare Advantage Network: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Loudoun Medical Group Joins Humana Medicare Advantage Network


Loudoun Medical Group, P.C. (LMG), one of the largest and most diverse physician-owned, multi-specialty group practices in Virginia, and leading health and well-being company Humana Inc. (NYSE

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope


Simulations Plus, Inc. (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to the

Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced a corporate

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US


Regulatory News:



GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal

DGAP-News: MorphoSys AG: Unternehmenskalender 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Unternehmenskalender 2022
DGAP-News: MorphoSys AG: Unternehmenskalender 2022
DGAP-News: MorphoSys AG: Corporate Calendar 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Corporate Calendar 2022
DGAP-News: MorphoSys AG: Corporate Calendar 2022
DGAP-News: MorphoSys AG: Unternehmenskalender 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Unternehmenskalender 2022
DGAP-News: MorphoSys AG: Unternehmenskalender 2022
DGAP-News: MorphoSys AG: Corporate Calendar 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Corporate Calendar 2022
DGAP-News: MorphoSys AG: Corporate Calendar 2022